Summit is at a very exciting stage in its development having met its primary objective in its Phase Ib modified diet clinical trial of SMT C1100 for Duchenne Muscular Dystrophy (DMD) last month. As a result, we increase our intrinsic value per share from 245p to 289p. Top line Phase II data from its C. difficile antibiotic, SMT 19969, is due in Q4 2015. Ahead of this C. diff data we evaluate the upside potential of SMT 19969 as it continues its positive development. As an illustration, our intri ....
